vs
BioRestorative Therapies, Inc.（BRTX）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
Sotera Health Co的季度营收约是BioRestorative Therapies, Inc.的15481.7倍（$303.4M vs $19.6K）。Sotera Health Co净利率更高（11.5% vs -16365.5%，领先16377.0%）。Sotera Health Co同比增速更快（4.6% vs -54.7%）。Sotera Health Co自由现金流更多（$52.4M vs $-2.5M）。过去两年Sotera Health Co的营收复合增速更高（10.6% vs -25.2%）
BioRestorative Therapies, Inc.是一家临床阶段生物技术企业，专注于创新再生医学疗法的研发，核心管线覆盖慢性腰痛、代谢类疾病等未被满足的医疗需求领域，主要面向北美市场，推进细胞类创新候选治疗产品的临床开发工作。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
BRTX vs SHC — 直观对比
营收规模更大
SHC
是对方的15481.7倍
$19.6K
营收增速更快
SHC
高出59.3%
-54.7%
净利率更高
SHC
高出16377.0%
-16365.5%
自由现金流更多
SHC
多$54.9M
$-2.5M
两年增速更快
SHC
近两年复合增速
-25.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6K | $303.4M |
| 净利润 | $-3.2M | $34.8M |
| 毛利率 | 91.7% | 54.7% |
| 营业利润率 | -19516.8% | 23.2% |
| 净利率 | -16365.5% | 11.5% |
| 营收同比 | -54.7% | 4.6% |
| 净利润同比 | -96.0% | 182.8% |
| 每股收益（稀释后） | $-0.31 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRTXSHC
| Q4 25 | $19.6K | $303.4M | ||
| Q3 25 | $11.8K | $311.3M | ||
| Q2 25 | $303.3K | $294.3M | ||
| Q1 25 | $25.0K | $254.5M | ||
| Q4 24 | $43.3K | $290.2M | ||
| Q3 24 | $233.6K | $285.5M | ||
| Q2 24 | $89.1K | $276.6M | ||
| Q1 24 | $35.0K | $248.2M |
净利润BRTXSHC
| Q4 25 | $-3.2M | $34.8M | ||
| Q3 25 | $-3.0M | $48.4M | ||
| Q2 25 | $-2.7M | $8.0M | ||
| Q1 25 | $-5.3M | $-13.3M | ||
| Q4 24 | $-1.6M | $12.3M | ||
| Q3 24 | $-1.1M | $17.0M | ||
| Q2 24 | $-4.0M | $8.8M | ||
| Q1 24 | $-2.2M | $6.3M |
毛利率BRTXSHC
| Q4 25 | 91.7% | 54.7% | ||
| Q3 25 | 10.4% | 57.0% | ||
| Q2 25 | 97.1% | 56.6% | ||
| Q1 25 | 88.4% | 53.2% | ||
| Q4 24 | 92.3% | 56.6% | ||
| Q3 24 | 92.2% | 55.4% | ||
| Q2 24 | 92.7% | 55.2% | ||
| Q1 24 | 100.0% | 51.2% |
营业利润率BRTXSHC
| Q4 25 | -19516.8% | 23.2% | ||
| Q3 25 | -31432.3% | 23.4% | ||
| Q2 25 | -1089.8% | 6.4% | ||
| Q1 25 | -19230.1% | -5.8% | ||
| Q4 24 | -6212.8% | 30.0% | ||
| Q3 24 | -979.0% | 28.2% | ||
| Q2 24 | -2770.8% | 27.8% | ||
| Q1 24 | -11740.7% | 21.4% |
净利率BRTXSHC
| Q4 25 | -16365.5% | 11.5% | ||
| Q3 25 | -25748.1% | 15.5% | ||
| Q2 25 | -875.8% | 2.7% | ||
| Q1 25 | -21359.2% | -5.2% | ||
| Q4 24 | -3778.6% | 4.2% | ||
| Q3 24 | -467.2% | 6.0% | ||
| Q2 24 | -4521.4% | 3.2% | ||
| Q1 24 | -6352.2% | 2.5% |
每股收益（稀释后）BRTXSHC
| Q4 25 | $-0.31 | $0.12 | ||
| Q3 25 | $-0.33 | $0.17 | ||
| Q2 25 | $-0.30 | $0.03 | ||
| Q1 25 | $-0.64 | $-0.05 | ||
| Q4 24 | $-0.20 | $0.05 | ||
| Q3 24 | $-0.13 | $0.06 | ||
| Q2 24 | $-0.50 | $0.03 | ||
| Q1 24 | $-0.33 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $344.6M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $356.7K | $606.0M |
| 总资产 | $4.1M | $3.3B |
| 负债/权益比越低杠杆越低 | — | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资BRTXSHC
| Q4 25 | $3.0M | $344.6M | ||
| Q3 25 | $4.5M | $299.2M | ||
| Q2 25 | $7.4M | $332.4M | ||
| Q1 25 | $9.1M | $304.4M | ||
| Q4 24 | $10.7M | $277.2M | ||
| Q3 24 | $13.1M | $306.7M | ||
| Q2 24 | $14.7M | $246.1M | ||
| Q1 24 | $16.4M | $261.1M |
总债务BRTXSHC
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益BRTXSHC
| Q4 25 | $356.7K | $606.0M | ||
| Q3 25 | $2.2M | $550.5M | ||
| Q2 25 | $4.8M | $511.3M | ||
| Q1 25 | $6.1M | $414.1M | ||
| Q4 24 | $8.5M | $404.9M | ||
| Q3 24 | $10.0M | $470.2M | ||
| Q2 24 | $10.8M | $422.8M | ||
| Q1 24 | $14.5M | $429.4M |
总资产BRTXSHC
| Q4 25 | $4.1M | $3.3B | ||
| Q3 25 | $5.6M | $3.2B | ||
| Q2 25 | $8.5M | $3.2B | ||
| Q1 25 | $10.3M | $3.1B | ||
| Q4 24 | $12.3M | $3.1B | ||
| Q3 24 | $14.6M | $3.1B | ||
| Q2 24 | $16.1M | $3.1B | ||
| Q1 24 | $18.0M | $3.1B |
负债/权益比BRTXSHC
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | $-2.5M | $52.4M |
| 自由现金流率自由现金流/营收 | -12728.8% | 17.3% |
| 资本支出强度资本支出/营收 | 406.5% | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | — | $149.2M |
8季度趋势，按日历期对齐
经营现金流BRTXSHC
| Q4 25 | $-2.4M | $103.1M | ||
| Q3 25 | $-2.9M | $71.2M | ||
| Q2 25 | $-2.7M | $57.4M | ||
| Q1 25 | $-2.8M | $55.5M | ||
| Q4 24 | $-2.3M | $55.7M | ||
| Q3 24 | $-1.7M | $97.5M | ||
| Q2 24 | $-1.9M | $61.3M | ||
| Q1 24 | $-2.3M | $9.7M |
自由现金流BRTXSHC
| Q4 25 | $-2.5M | $52.4M | ||
| Q3 25 | — | $35.0M | ||
| Q2 25 | — | $26.2M | ||
| Q1 25 | $-2.8M | $35.6M | ||
| Q4 24 | — | $-10.2M | ||
| Q3 24 | $-1.8M | $61.1M | ||
| Q2 24 | — | $19.4M | ||
| Q1 24 | — | $-25.2M |
自由现金流率BRTXSHC
| Q4 25 | -12728.8% | 17.3% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 8.9% | ||
| Q1 25 | -11260.7% | 14.0% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | -752.6% | 21.4% | ||
| Q2 24 | — | 7.0% | ||
| Q1 24 | — | -10.2% |
资本支出强度BRTXSHC
| Q4 25 | 406.5% | 16.7% | ||
| Q3 25 | 0.0% | 11.6% | ||
| Q2 25 | 0.0% | 10.6% | ||
| Q1 25 | 145.6% | 7.8% | ||
| Q4 24 | — | 22.7% | ||
| Q3 24 | 25.0% | 12.7% | ||
| Q2 24 | — | 15.2% | ||
| Q1 24 | — | 14.1% |
现金转化率BRTXSHC
| Q4 25 | — | 2.96× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 7.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.52× | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 7.00× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRTX
暂无分部数据
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
